Florian Stul
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Florian Stul has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
An De Sutter
Affiliation Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Centre for Family Medicine, Ghent University, Ghent, Belgium
1 shared publication- An Piessens
Affiliation Research Centre Pedagogy in Practice, KdG University of Applied Sciences and Arts, Antwerp, Belgium
1 shared publication Ann Van Den Bruel
Affiliation Department of Public Health and Primary Care, Academic Centre for General Practice, KU Leuven, Leuven, Belgium
1 shared publicationAnn Van Hecke
Affiliation Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, University Centre for Nursing and Midwifery, Ghent University, Ghent, Belgium
1 shared publication- Ellen Van Leeuwen
Ghent University
1 shared publication - Els Mehuys
Ghent University
1 shared publication
Latest Publications
- 2 November 2025
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 80 (6) , 175-185
Community pharmacists’ experiences with the new tapering program for benzodiazepines and Z-drugs in Belgium
Long-term use of benzodiazepines and Z-drugs (BZRA) remains widespread, despite guidelines recommending short-term use and highlighting the harms. On 1 February 2023, a tapering pilot program was launched in Belgium to facilitate deprescribing BZRA by enabling community pharmacists (CPs) to compound capsules with stepwise gradual dose reductions. This study aims to explore the CPs' role in this program and the barriers and facilitators they encounter within the program. A cross-sectional survey study evaluating barriers and facilitators was conducted. Participants were randomly selected from the National Database of Community Pharmacies. Results were analyzed descriptively using the Theoretical Domains Framework to identify influences on behaviour change. Out of 2000 CPs contacted, 328 participants (16.4%) completed the survey. CPs rated their overall satisfaction with the program with a mean score of 7.4/10. Key facilitators identified included the relationship of trust between the patient, CP and general practitioner (GP), the patient's confidence in the CP's role in the program and the specific program elements. The most significant barriers were the CPs' perceived lack of interest from GPs and patients. The Belgian pilot program has been positively received by CPs. Success factors are the interdisciplinary collaboration (social influences) and the specific elements of the program itself (environmental context and resources). To better understand the factors influencing participation, a qualitative in-depth exploration of CPs, GPs and patients perspectives of the tapering program is recommended. Furthermore, implementation outcomes, the sustainability of BZRA cessation and the benefits patients experience from discontinuation need to be investigated.
- 2 November 2025
- Published by Taylor & Francis in Acta Clinica Belgica
- Vol. 80 (6) , 175-185
Community pharmacists’ experiences with the new tapering program for benzodiazepines and Z-drugs in Belgium
Long-term use of benzodiazepines and Z-drugs (BZRA) remains widespread, despite guidelines recommending short-term use and highlighting the harms. On 1 February 2023, a tapering pilot program was launched in Belgium to facilitate deprescribing BZRA by enabling community pharmacists (CPs) to compound capsules with stepwise gradual dose reductions. This study aims to explore the CPs' role in this program and the barriers and facilitators they encounter within the program. A cross-sectional survey study evaluating barriers and facilitators was conducted. Participants were randomly selected from the National Database of Community Pharmacies. Results were analyzed descriptively using the Theoretical Domains Framework to identify influences on behaviour change. Out of 2000 CPs contacted, 328 participants (16.4%) completed the survey. CPs rated their overall satisfaction with the program with a mean score of 7.4/10. Key facilitators identified included the relationship of trust between the patient, CP and general practitioner (GP), the patient's confidence in the CP's role in the program and the specific program elements. The most significant barriers were the CPs' perceived lack of interest from GPs and patients. The Belgian pilot program has been positively received by CPs. Success factors are the interdisciplinary collaboration (social influences) and the specific elements of the program itself (environmental context and resources). To better understand the factors influencing participation, a qualitative in-depth exploration of CPs, GPs and patients perspectives of the tapering program is recommended. Furthermore, implementation outcomes, the sustainability of BZRA cessation and the benefits patients experience from discontinuation need to be investigated.
- Open Access
- 3 February 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (2) , e0315247
Do health professionals know about overdiagnosis in screening, and how are they dealing with it? A mixed-methods systematic scoping review
Introduction: Medical screening is a major driver of overdiagnosis, which should be considered when making an informed screening decision. Health professionals (HPs) often initiate screening and are therefore responsible for informing eligible screening participants about the benefits and harms of screening. However, little is known about HPs’ knowledge of overdiagnosis and whether they are prepared to inform screening candidates about this risk and enable people to make an informed screening decision. Methods: This is a systematic review of studies examining HPs’ knowledge and perception of overdiagnosis, whether it affects their position on offering screening, and their willingness to inform screening candidates about overdiagnosis. We conducted systematic searches in MEDLINE, Embase, Web of Science, Scopus, CINAHL, and PsycArticles without language restrictions. Two authors analysed the qualitative and quantitative data separately. Confidence in the findings of the qualitative data was assessed using the GRADE-CERQual approach. Results: We included 23 publications after screening 9786 records. No studies directly examined HPs’ knowledge of overdiagnosis. HPs’ perceptions of overdiagnosis varied widely, from considering it a significant harm to seeing it as negligible. This seems linked to their overall beliefs about the benefits and harms of screening and to their position on offering screening, which varies from discouraging to actively promoting it. HPs also hold diverging approaches to informing screening candidates about overdiagnosis, from providing detailed explanations to limited or no information. Conclusion: There is a lack of research on HPs’ knowledge of overdiagnosis, however, HPs who do know about overdiagnosis attribute substantially different levels of harm to it. This seems intertwined with their overall beliefs about the benefits of screening, their position towards offering screening, and their willingness to inform screening candidates about overdiagnosis. This has important implications for the public’s right to evidence-based information and compromises an individual’s right to make an informed screening decision.
- 3 February 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (2) , e0315247
Open AccessDo health professionals know about overdiagnosis in screening, and how are they dealing with it? A mixed-methods systematic scoping review
Introduction: Medical screening is a major driver of overdiagnosis, which should be considered when making an informed screening decision. Health professionals (HPs) often initiate screening and are therefore responsible for informing eligible screening participants about the benefits and harms of screening. However, little is known about HPs’ knowledge of overdiagnosis and whether they are prepared to inform screening candidates about this risk and enable people to make an informed screening decision. Methods: This is a systematic review of studies examining HPs’ knowledge and perception of overdiagnosis, whether it affects their position on offering screening, and their willingness to inform screening candidates about overdiagnosis. We conducted systematic searches in MEDLINE, Embase, Web of Science, Scopus, CINAHL, and PsycArticles without language restrictions. Two authors analysed the qualitative and quantitative data separately. Confidence in the findings of the qualitative data was assessed using the GRADE-CERQual approach. Results: We included 23 publications after screening 9786 records. No studies directly examined HPs’ knowledge of overdiagnosis. HPs’ perceptions of overdiagnosis varied widely, from considering it a significant harm to seeing it as negligible. This seems linked to their overall beliefs about the benefits and harms of screening and to their position on offering screening, which varies from discouraging to actively promoting it. HPs also hold diverging approaches to informing screening candidates about overdiagnosis, from providing detailed explanations to limited or no information. Conclusion: There is a lack of research on HPs’ knowledge of overdiagnosis, however, HPs who do know about overdiagnosis attribute substantially different levels of harm to it. This seems intertwined with their overall beliefs about the benefits of screening, their position towards offering screening, and their willingness to inform screening candidates about overdiagnosis. This has important implications for the public’s right to evidence-based information and compromises an individual’s right to make an informed screening decision.